ArticleNPJ vaccines2018

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial.

Rhea N Coler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.